Martin Auster

Q: How accurate are Martin Auster's stock ratings?

About 47% of Martin's ratings were profitable over a one-year hold, with an average return of +5.0% per rating, measured by 13Foresight from historical prices.

Q: How is Martin ranked?

Martin Auster is ranked #2934 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Raymond James

Wall Street Analyst

★☆☆☆☆

#2934

on 13Foresight · ranked by our own returns

47%

Success Rate

+5.0%

Average Return

17 of 36 calls profitable · -8.8% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 47% of Martin Auster's ratings turned a profit when each position was held for 1 year — averaging +5.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

29 Buy 3 Hold 0 Sell

Martin's Stock Coverage 38 ratings · 2026-08-08

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
DYN Dyne Therapeutics	Aug 04, 2026	BUY	Strong Buy +52.8% avg upside 31 analysts	$40.00 52.46% Upside	+1.1%	·
PHAT Phathom Pharmaceuticals	Jul 31, 2026	BUY	Strong Buy +210.9% avg upside 14 analysts	$21.00 145.69% Upside	-2.3%	·
ALNY Alnylam Pharma	Jul 31, 2026	BUY	Strong Buy +47.8% avg upside 51 analysts	$420.00 91.60% Upside	+4.7%	·
IBIO Ibio	Jun 08, 2026	BUY	Strong Buy +314.5% avg upside 11 analysts	$5.00 254.61% Upside	-18.5%	·
SEPN Septerna, Inc.	Jun 08, 2026	BUY	Strong Buy +18.0% avg upside 12 analysts	$53.00 36.58% Upside	+30.0%	·
EWTX Edgewise Therapeutics	Jun 01, 2026	BUY	Strong Buy +4.6% avg upside 15 analysts	$66.00 51.73% Upside	-60.8%	·
EQ Equillium	May 28, 2026	BUY	Strong Buy +344.6% avg upside 16 analysts	$7.00 231.81% Upside	-25.7%	·
BBIO BridgeBio Pharma	May 26, 2026	HOLD	Strong Buy +10.2% avg upside 34 analysts	—	+22.2%	·
TECX Tectonic Therapeutic	May 26, 2026	BUY	Strong Buy +82.5% avg upside 24 analysts	$81.00 161.56% Upside	+3.3%	·
SYRE Spyre Therapeutics	Apr 10, 2026	BUY	Strong Buy -12.8% avg upside 23 analysts	$80.00 23.72% Downside	+104.5%	·
SRRK Scholar Rock Holding	Mar 30, 2026	BUY	Strong Buy +8.5% avg upside 23 analysts	$60.00 13.31% Upside	+20.7%	·
MAZE Maze Therapeutics, Inc.	Mar 25, 2026	BUY	Strong Buy +120.0% avg upside 12 analysts	$56.00 95.54% Upside	-9.7%	·
EVMN Evommune, Inc.	Jan 26, 2026	BUY	Strong Buy +196.8% avg upside 12 analysts	$40.00 184.14% Upside	-28.1%	·
IRON Disc Medicine	Jan 13, 2026	BUY	Strong Buy +12.2% avg upside 21 analysts	$117.00 51.11% Upside	+3.3%	·
WVE Wave Life Sciences	Jan 13, 2026	BUY	Strong Buy +238.5% avg upside 28 analysts	$26.00 326.16% Upside	-57.6%	·
ASND Ascendis Pharma	Oct 17, 2025	BUY	Strong Buy +8.4% avg upside 24 analysts	$271.00 6.02% Upside	+21.3%	·
CYTK Cytokinetics	Jul 30, 2025	HOLD	Strong Buy +16.3% avg upside 36 analysts	—	+122.3%	·
SPRB Spruce Biosciences	Nov 16, 2021	BUY	Strong Buy +123.9% avg upside 15 analysts	$6.00 87.19% Downside	·	·
BMRN BioMarin Pharmaceutical	Oct 28, 2021	BUY	Strong Buy +49.1% avg upside 52 analysts	$100.00 56.79% Upside	+11.0%	·
FULC Fulcrum Therapeutics	Mar 22, 2021	BUY	Hold +129.7% avg upside 14 analysts	$26.00 568.33% Upside	+55.3%	·
DMRA Damora Therapeutics	Mar 16, 2021	BUY	Strong Buy -3.3% avg upside 20 analysts	$12.00 59.88% Downside	-75.8%	·
SLDB Solid Biosciences	Mar 16, 2021	HOLD	Strong Buy +87.8% avg upside 23 analysts	$8.00 4.71% Downside	-81.3%	·
STOK Stoke Therapeutics	Mar 10, 2021	BUY	Strong Buy +22.6% avg upside 18 analysts	$58.00 77.26% Upside	-61.8%	·
SRPT Sarepta Therapeutics	Mar 02, 2021	HOLD	Buy +255.4% avg upside 49 analysts	$72.00 329.08% Upside	-10.5%	·
UTHR United Therapeutics	Feb 22, 2021	BUY	Buy -19.7% avg upside 26 analysts	$196.00 63.66% Downside	+11.1%	·
ALXO ALX Oncology Holdings	Feb 11, 2021	BUY	Strong Buy +754.4% avg upside 11 analysts	$98.00 4566.59% Upside	·	·
RARE Ultragenyx Pharmaceutical	Jan 25, 2021	HOLD	Strong Buy +157.0% avg upside 36 analysts	$99.00 282.14% Upside	-52.9%	·
INSM Insmed	Jan 19, 2021	BUY	Strong Buy +34.9% avg upside 37 analysts	$60.00 54.15% Downside	-43.7%	·
PTCT PTC Therapeutics	Jan 11, 2021	HOLD	Strong Buy +11.3% avg upside 29 analysts	$54.00 26.43% Downside	-39.0%	·
QURE uniQure	Nov 20, 2020	BUY	Strong Buy +27.9% avg upside 29 analysts	$78.00 68.11% Upside	-35.7%	·
IRWD Ironwood Pharma	Nov 06, 2020	HOLD	Buy +175.6% avg upside 23 analysts	$12.00 177.81% Upside	+20.9%	·
NTLA Intellia Therapeutics	Nov 05, 2020	HOLD	Buy +226.0% avg upside 37 analysts	$24.00 101.10% Upside	+375.7%	·
KURA Kura Oncology	Oct 08, 2020	BUY	Strong Buy +172.3% avg upside 26 analysts	$43.00 349.22% Upside	-43.3%	·
QNCX Quince Therapeutics	Sep 15, 2020	SELL	Buy +614.8% avg upside 16 analysts	$14.00 53.56% Downside	·	·
CYCN Cyclerion Therapeutics	Aug 03, 2020	HOLD	Strong Buy +157.2% avg upside 2 analysts	$5.00 39.98% Upside	·	·
ANAB AnaptysBio	Jul 07, 2020	HOLD	Strong Buy +28.5% avg upside 26 analysts	$16.00 71.64% Downside	+16.3%	·
OBSEF ObsEva	Nov 07, 2019	HOLD	Buy +10799900.0% avg upside 8 analysts	$4.00 3999899.98% Upside	·	·
PDSB PDS Biotechnology	Jan 18, 2018	BUY	Strong Buy +1865.2% avg upside 11 analysts	$17.00 2092.75% Upside	·	·

🔒 33 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Martin Auster — Frequently Asked Questions

How accurate are Martin Auster's stock ratings?

Based on the calls 13Foresight could measure, about 47% of Martin's ratings were profitable over a one-year hold, with an average return of +5.0% per rating, or -8.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Martin ranked on 13Foresight?

Martin Auster is currently ranked #2934 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Martin cover?

Martin most recently has ratings on DYN, PHAT, ALNY, IBIO, SEPN, EWTX, EQ, BBIO, TECX, SYRE, SRRK, MAZE and 26 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Martin Auster

Rating Distribution

Welcome to 13Foresight!